Glikokortykosteroidy a metabolizm i wzrost kosci

• Autorzy: Sliwa E , Studzinski T. , Tatara M.R.

Warianty tytułu

EN

Glucocorticoids and the metabolism and skeletal system growth

• Języki publikacji: PL

Abstrakty

EN

Glucocorticoids play an important role in general growth and the maintenance of bone mass in the skeleton. Steroid therapy induces bone loss and influences the transcription of some regulatory factors determining the ratio of bone turnover. Glucocorticoids increase bone resorption and decrease bone formation which leads to diminishing bone mass and bone mineral density. Osteoporosis is globally one of the most common metabolic bone diseases, and has increasingly been recognized as being a major public health issue. Glucocorticoids increase the risk of rib and limb bone fractures by modifying and decreasing bone quality. Glucocorticoids are very often used as anti-inflammatory and immunosuppressive drugs for serious rheumatoid arthritis and other systemic diseases in large groups of young children, and Glucocorticoids therapy is also used for children and youth having asthma as well as being administered during pregnancy in order to improve lung morphology in premature fetuses. No glucocorticoid drugs which would act without negative side effects are currently available. This review presents the mechanisms of glucocorticoid action based on the latest research and newest factors controlling bone remodeling such as osteoprotegerin and osteoprotegerin-ligands.

Słowa kluczowe

PL

metabolizm zwierzat; rozwoj; deksametazon; tkanka kostna; kosci; glikokortykosteroidy; wzrost

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2006
• Tom: 62
• Numer: 04
• Strony: 377-379
• Opis fizyczny: s.377-379,bibliogr.

Twórcy

autor

Sliwa E

• Akademia Rolnicza, ul.Akademicka 12, 20-033 Lublin

autor

Studzinski T.

autor

Tatara M.R.

Bibliografia

• 1.Advani S., LaFrancis D., Bogdanovic E., Taxel P., Raisz L. G., Kream B. E.: Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice. Bone 1997, 20, 41-46.
• 2.Blondelon D., Adolphe M., Zizine L., Lechat P.: Evidence for glucocorticoid receptors in cultured rabbit articular chondrocytes. Feb. Letters 1980, 117, 195-198.
• 3.Bondy P., Cohn L.: Działanie fizjologiczne i wybrane zagadnienia farmakologii glikokortykosteroidów. Weterynaria po Dyplomie 2003, 4, 10-13.
• 4.Bukowczan Z., Kurzawa R., Bukowczan M.: Molekularny mechanizm dzia³ania glikokortykosteroidów (GKS). Terapia 2002, 130, 434-438.
• 5.Burrin D. G., Wester T. J., Davis T., Fiorotto M., Chang X.: Dexamethasone inhibits small intestinal growth via increased protein catabolism in neonatal pigs. Am. J. Physiol. 1999, 276, E262-E276.
• 6.Carroll J.: Dexamethasone treatment at birth enhances neonatal growth in swine. Domest. Anim. Endocrinol. 2001, 21, 97-109.
• 7.Chwaliñska-Sadowska M.: Osteoporoza: fakty i perspektywy. Terapia 2001, 108, 12-15.
• 8.Ferretti J. L., Capozza R. F., Cointry G. R., Delgado C. J., Zanchetta J. R.: Monophasic dose-response curves of bethamethasone on geometric and mechanical properties of femur diaphyses in growing rats. Bone 1995, 16, 103-108.
• 9.Ferretti J. L., Gaffuri O., Capozza R., Cointry G., Bozzini C., Olivera M., Zanchetta J. R., Bozzini C. E.: Dexamethasone effects on mechanical, geometric and densitometric properties of rat diaphyses as described by peripheral quantitative computerized tomography and bending tests. Bone 1995, 16, 119-124.
• 10.Egerman R., Anderson R., Umstot E., Carr T., Sibai B.: A comparison of the bioavailability of oral and intramuscular dexamethasone in women in late pregnancy. Obstet. Gynecol. 1997, 89, 276-280.
• 11.Gu Y., Genever P. G., Skerry T. M., Publicover S. J.: The NMDA type glutamate receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors. Calcified Tissue Int. 2002, 70, 194-203.
• 12.Hofbauer L. C.: The roles of osteoprotegerin and osteoprotegerin-ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 2000, 15, 2-6.
• 13.Horst-Sikorska W.: Obraz kliniczny i leczenie osteoporozy wtórnej wywołanej chorobami endokrynologicznymi. Terapia 2002, 1, 23-27.
• 14. Jędrzejczuk D.: Otyłość a osteoporoza. Terapia 2001, 1, 40-43.
• 15. Jobe A. H., Wada N., Berry L. M., Ikegami M., Erwin M. G.: Single and repetitive maternal glucocorticoids exposures reduce fetal growth in sheep. Am. J. Obstet. Gynecol. 1998, 178, 880-885.
• 16.Lacey D. L.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93, 304-308.
• 17.Leszczyñski P., £ącki J., Mackiewicz S.: Osteoporoza posteroidowa patomechanizm, zapobieganie i leczenie. Postępy Nauk Medycznych 2000, 2, 56-58.
• 18.Michel C., Cabanac M.: Effects of dexamethasone on the body weight set point of rats. Physiol. Behav. 1999, 68, 145-150.
• 19.Migliazza L., Xia H. M., Arnaiz A., Alvarez J. I., Alfonso L. F., Diez-Pardo J. A., Valls A., Tovar J. A.: Prenatal dexamethasone rescues heart hypoplasia in fetal rats with congenital diaphragmatic hernia. J. Pediatr. Surg. 2000, 35, 1757-1761.
• 20.Nakai A., Shibazaki Y., Taniuchi Y., Oya A., Asakura H., Koshino T., Araki T.: Effect of dexamethasone on mitochondrial maturation in the fetal rat brain. Am. J. Obstet. Gynecol. 2002, 186, 574-578.
• 21.Orzechowski A., Ostaszewski P., Wilczak J., Jank M., Ba³asiñska B., Warêski P., Fuller J.: Rats with a glucocorticoid-induced catabolic state show symptoms of oxidative stress and spleen atrophy: the effects of age and recovery. J. Vet. Med. A 2002, 49, 256-263.
• 22.Orzechowski A., Ostaszewski P., Wilczak J., Jank M., Bałasiñska B., Grzelkowska K., Ploszaj T., Olczak J., Mrówczyñska A.: Excess of glucocorticoids impairs whole-body antioxidant status in young rats. Relation to the effect of dexamethasone in soleus muscle and spleen. Horm. Metab. Res. 2000, 32, 174-180.
• 23.Puchnarewicz A., Tobolczyk J., Hofman J.: Zachowanie się stężenia osteokalcyny w surowicy dzieci chorych na astmę oskrzelową leczonych budezonidem wziewnym. Alergia Astma Immunologia 2003, 8, 98-102.
• 24.Skowroñska-Jóźwiak E., Białkowska J., Jabłkowski M., Lewiñski A.: Wpływ IGF-I oraz IGFBP-3 na gęstość mineralną kości u kobiet z przewlekłymi chorobami wątroby. Terapia 2002, 123, 361-365.
• 25.Smink J., Gresnigt M. G., Hamers N., Koedam J., Berger R., Buul-Offers S.: Short-term glucocorticoid treatment of prepubertal mice decreases growth and IGF-I expression in the growth plate. J. Endocrinol. 2003, 177, 381-388.
• 26.Śliwa E., Kowalik S., Tatara M. R., Studziñski T.: Effect of maternal administration of dexamethasone during last weeks of pregnancy on foetal skeletal system in pigs. Bulletin of the Veterinary Institute in Pulawy 2004, 48, 449-452.
• 27.Śliwa E., Kowalik S., Tatara M. R., Majcher P., Krupski W., Studziñski T.: Effects of dexamethasone on physical properties and mineral density of long bones in piglets. Bull. Vet. Inst. Pulawy 2005, 49, 97-100.
• 28.Śliwa E., Tatara M. R., Kowalik S., Krupski W., Majcher P., Piersiak T., Studziñski T.: Wpływ deksametazonu na wzrost i mineralizację układu kostnego w okresie prenatalnym u świñ. Medycyna Wet. (w druku).
• 29.Śliwa E., Wawrzyniak-Gacek A., Tatara M. R., Kowalik S., £uszczewska-Sierakowska I., Krupski W., Majcher P., Pierzynowski S. G., Studziñski T.: Wpływ deksametazonu i alfa-ketoglutaranu na wzrost i rozwój układu kostnego u świñ. Medycyna Wet. 2005, 61, 526-531.
• 30.Uhrynowska-Tyszkiewicz I., Kamiñski A., Dziedzic-Gocławska A.: Mechanizmy działania niektórych hormonów na procesy przebudowy tkanki kostnej. Terapia 2002, 123, 369-372.
• 31.Warenik-Szymankiewicz A.: Leczenie hormonalne osteoporozy w okresie postemenopauzalnym. Terapia 1999, 123, 366-369.
• 32.Wojtowicz A., Kossowska K., Malejczyk J.: Rola białka morfogenetycznego kości 6 (BMP-6) w regulacji różnicowania. Nowa Stomatologia 2001, 17, 88-90.
• 33.Vos P., Saladin R., Auwerx J., Staels B.: Induction of ob gene expression by corticosteroid is accompanied by body weight loss and reduced food intake. J. Biol. Cem. 1995, 27, 15958-15961.
• 34.Yasuda H.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoklastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc. Nation. Acad. Sci. USA 1998, 95, 3597-3606.